Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Pharma Announces Positive Results from Phase II BHT-II-002 Trial of Blautix in Irritable Bowel Syndrome","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"4D Pharma"},{"company":"GSK","sponsor":"Immutep","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Announces that the Phase II Ulcerative Colitis Study of GSK2831781 Has Been Discontinued","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"GSK"},{"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D pharma to Present Additional Data from Phase II Study of Blautix for Irritable Bowel Syndrome","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"4D Pharma"},{"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Pharma Presents Microbiome Analyses from Phase II Clinical Trial of Blautix\u00ae for IBS-C and IBS-D at Gastro 2021","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"4D Pharma"}]

4D Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

4D Pharma Presents Microbiome Analyses from Phase II Clinical Trial of Blautix® for IBS-C and IBS-D at Gastro 2021

Details:

Results demonstrate changes in gut microbiome structure following administration of Blautix (Blautia Hydrogenotrophica) in both IBS-C and IBS-D patients.

Lead Product(s): Blautia Hydrogenotrophica

Therapeutic Area: Gastroenterology Product Name: Blautix

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 09, 2021

ASK
US

Upload
your Pipeline Activity

4D Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

4D pharma to Present Additional Data from Phase II Study of Blautix for Irritable Bowel Syndrome

Details:

In Phase II trial, where Blautix demonstrated signals of clinical activity in both IBS-C and IBS-D, and a highly favorable safety and tolerability profile.

Lead Product(s): Blautia Hydrogenotrophica

Therapeutic Area: Gastroenterology Product Name: Blautix

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 17, 2021

ASK
US

Upload
your Pipeline Activity

GSK

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Immutep Announces that the Phase II Ulcerative Colitis Study of GSK2831781 Has Been Discontinued

Details:

GSK, has stopped its Phase II trial of anti-LAG3 cell depleting monoclonal antibody, GSK2831781 (derived from Immutep’s IMP731 antibody), in patients with active ulcerative colitis. The trial was stopped based on the assessment of clinical data of planned interim analysis.

Lead Product(s): IMP731

Therapeutic Area: Gastroenterology Product Name: GSK2831781

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Immutep

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 22, 2021

ASK
US

Upload
your Pipeline Activity

4D Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

4D Pharma Announces Positive Results from Phase II BHT-II-002 Trial of Blautix in Irritable Bowel Syndrome

Details:

The phase II trial showed that Blautix treatment resulted in: A statistically significant increase in overall response in pre-planned analysis of the combined IBS-C/D group compared to placebo; A positive, increase in overall response in both IBS-C and IBS-D cohorts.

Lead Product(s): Blautia Hydrogenotrophica

Therapeutic Area: Gastroenterology Product Name: Blautix

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 07, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY